美银证券发表报告指，再鼎医药(09688.HK) (ZLAB.US) 核心产品Zejula和Optune表现疲软，但VYVGART销售逐步提升，产品线发展取得进展。对该股2025和2026年的收入预测维持不变，但自2027年起收入预测上调超过5%。目标价从29美元和22.48港元分别上调至36.1美元和27.98港元。但由于核心产品增长放缓、短期正面消息已被市场消化，尽管产品线发展稳健， 评级由“买入”降至“中性”。(ha/k)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-28 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.